365 related articles for article (PubMed ID: 19098925)
1. Potential new drug targets for osteoporosis.
Deal C
Nat Clin Pract Rheumatol; 2009 Jan; 5(1):20-7. PubMed ID: 19098925
[TBL] [Abstract][Full Text] [Related]
2. Future therapeutic targets in osteoporosis.
Deal C
Curr Opin Rheumatol; 2009 Jul; 21(4):380-5. PubMed ID: 19461517
[TBL] [Abstract][Full Text] [Related]
3. Emerging anabolic treatments in osteoporosis.
Mosekilde L; Tørring O; Rejnmark L
Curr Drug Saf; 2011 Apr; 6(2):62-74. PubMed ID: 21524248
[TBL] [Abstract][Full Text] [Related]
4. New therapeutic targets for osteoporosis: beyond denosumab.
Lim V; Clarke BL
Maturitas; 2012 Nov; 73(3):269-72. PubMed ID: 22925430
[TBL] [Abstract][Full Text] [Related]
5. Osteoporosis: now and the future.
Rachner TD; Khosla S; Hofbauer LC
Lancet; 2011 Apr; 377(9773):1276-87. PubMed ID: 21450337
[TBL] [Abstract][Full Text] [Related]
6. The future of osteoporosis treatment - a research update.
Lippuner K
Swiss Med Wkly; 2012; 142():w13624. PubMed ID: 22815185
[TBL] [Abstract][Full Text] [Related]
7. Biological agents in management of osteoporosis.
Tella SH; Gallagher JC
Eur J Clin Pharmacol; 2014 Nov; 70(11):1291-301. PubMed ID: 25204309
[TBL] [Abstract][Full Text] [Related]
8. Mathematical Model of Bone Remodeling Captures the Antiresorptive and Anabolic Actions of Various Therapies.
Ross DS; Mehta K; Cabal A
Bull Math Biol; 2017 Jan; 79(1):117-142. PubMed ID: 27905067
[TBL] [Abstract][Full Text] [Related]
9. Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
Ishtiaq S; Fogelman I; Hampson G
J Endocrinol Invest; 2015 Jan; 38(1):13-29. PubMed ID: 25194424
[TBL] [Abstract][Full Text] [Related]
10. Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives.
Baron R; Hesse E
J Clin Endocrinol Metab; 2012 Feb; 97(2):311-25. PubMed ID: 22238383
[TBL] [Abstract][Full Text] [Related]
11. Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches.
Cosman F
Curr Osteoporos Rep; 2014 Dec; 12(4):385-95. PubMed ID: 25341476
[TBL] [Abstract][Full Text] [Related]
12. Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis.
Chew CK; Clarke BL
Maturitas; 2017 Mar; 97():53-60. PubMed ID: 28159062
[TBL] [Abstract][Full Text] [Related]
13. New treatment modalities in osteoporosis.
Canalis E
Endocr Pract; 2010; 16(5):855-63. PubMed ID: 20350910
[TBL] [Abstract][Full Text] [Related]
14. Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis.
Bilezikian JP; Rubin MR
Curr Osteoporos Rep; 2006 Mar; 4(1):5-13. PubMed ID: 16527002
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)].
Quemerais-Durieu MA; Kerlan V; Chabre O
Ann Endocrinol (Paris); 2011 Oct; 72 Suppl 1():S15-22. PubMed ID: 22008272
[TBL] [Abstract][Full Text] [Related]
16. New understanding and treatments for osteoporosis.
Mazziotti G; Bilezikian J; Canalis E; Cocchi D; Giustina A
Endocrine; 2012 Feb; 41(1):58-69. PubMed ID: 22180055
[TBL] [Abstract][Full Text] [Related]
17. [Bone remodeling: new therapeutic approaches].
Ferrari S
Rev Med Suisse; 2009 Jun; 5(207):1325-8. PubMed ID: 19626933
[TBL] [Abstract][Full Text] [Related]
18. Future developments in osteoporosis therapy.
Ng KW
Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):371-84. PubMed ID: 19857200
[TBL] [Abstract][Full Text] [Related]
19. [Regulation of bone metabolism in osteoporosis : novel drugs for osteoporosis in development].
Jakob F; Genest F; Baron G; Stumpf U; Rudert M; Seefried L
Unfallchirurg; 2015 Nov; 118(11):925-32. PubMed ID: 26471379
[TBL] [Abstract][Full Text] [Related]
20. Perspectives on osteoporosis therapies.
Cairoli E; Zhukouskaya VV; Eller-Vainicher C; Chiodini I
J Endocrinol Invest; 2015 Mar; 38(3):303-11. PubMed ID: 25577263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
